Clinical Update: Navigating the Complexities of Autoimmune Retinopathy (AIR)
Autoimmune retinopathy (AIR) remains one of the most challenging diagnoses in the retina clinic due to its heterogeneous presentation and overlap with inherited retinal dystrophies (IRDs). However, recent advancements in multimodal imaging and biologic therapies are refining our ability to diagnose and treat this vision-threatening condition.
Pathophysiology and Classification
AIR is driven by immune-mediated damage to retinal cells through humoral and cellular mechanisms. The disease is broadly categorized into:
- Paraneoplastic AIR (pAIR): Including Cancer-Associated Retinopathy (CAR) and Melanoma-Associated Retinopathy (MAR), often triggered by molecular mimicry between tumor antigens and retinal proteins.
- Nonparaneoplastic AIR (npAIR): Occurs without systemic malignancy, possibly triggered by environmental or infectious factors.
- ARRON: Autoimmune-related retinopathy and optic neuropathy, involving the optic nerve.
The Diagnostic Challenge: Moving Beyond Serum ARAs
While antiretinal antibodies (ARAs) such as recoverin and alpha-enolase are diagnostic hallmarks, they lack high specificity and can be found in healthy individuals. Consequently, the AAO Task Force recommends a diagnosis based on a combination of:
- Subjective or objective progression over 6 months.
- Minimal intraocular inflammation (<1+ cell).
- OCT showing outer retinal disruption (often foveal-sparing).
- FAF abnormalities consistent with AIR.
- ERG showing reduced rod and cone responses.
- Positive ARAs.
Multimodal Imaging Spotlight: The “Yang” Finding
Standard multimodal imaging often reveals ellipsoid zone (EZ) loss and outer nuclear layer thinning on OCT, and hyperautofluorescent macular rings on FAF.
A critical novel finding by Yang et al. (2024) has added a specific marker to our diagnostic toolkit: multifocal circular perivascular lesions on FAF. These lesions are initially hyperautofluorescent, become hypoautofluorescent over time, and correspond to subretinal hyperreflective foci on OCT. While present in only 24% of cases, this perivascular distribution is a vital differentiator as it is rarely seen in IRDs.
Management Strategies
Treatment aims to halt progression through a stepwise escalation of immunosuppression:
- First-Line: Systemic or local corticosteroids and conventional agents like mycophenolate mofetil.
- Biologics: Rituximab (anti-CD20) has shown high efficacy in achieving visual stability, especially when initiated early. IVIG is a major therapeutic pillar; recent data indicates IVIG-treated patients are significantly more likely to maintain visual acuity and 30Hz flicker ERG responses compared to untreated cohorts.
- Emerging: JAK inhibitors and anti-IL-6 agents (e.g., tocilizumab) are currently under exploration for refractory cases.
Prognostic Pearls
Timing is the most significant predictor of outcome. Early intervention—specifically within the first few months of symptom onset—correlates with the most favorable results. Furthermore, improvement in visual field area within the first 6 months of treatment serves as a strong predictor of long-term visual acuity improvement.
Reference
Elbasiony E, Hu JCW, McKay KM, Sobrin L. Update on autoimmune retinopathy: diagnosis and management. Curr Opin Ophthalmol. 2025;36(6):497-506. doi:10.1097/ICU.0000000000001162.
